Q2 2021 Orexo AB Earnings Call Transcript
Hello, and welcome to the Orexo AB Q2 report of 2021. (Operator Instructions)
Today, I'm pleased to present Nikolaj Sørensen, Chief Executive Officer. Please begin your meeting.
¸ - ()-&
Thank you very much, and again, welcome to the first half results for Orexo. It's no doubt today has been a sweaty day not only due to the heat wave in Sweden, but also with looking at our share price. However, when I'm looking into our [Q] report and looking at the progress we have made on both ZUBSOLV and also on our digital therapies, I think there are some quite strong reasons to be optimistic about the development moving forward.
And with that, I will start the presentation, and I will go into Page #4. So Page 4. A short summary of the quarter here. So if we look at the U.S. Pharma business, we have seen a stable sales comparing to the last quarter. The positive part is that our core segment, the open market, in particular, the open commercial
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |